Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why NetEase Shares Are Falling

NetEase Inc (NASDAQ: NTES) shares are trading lower by 2.98% to $95.52 during Tuesday's session. Shares of several Chinese stocks are trading lower after China's central bank made cuts to its one-year loan prime rate and five-year rate amid attempts to stimulate the
byHenry Khederian
June 20, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

NetEase Inc (NASDAQ:NTES) shares are trading lower by 2.98% to $95.52 during Tuesday’s session. Shares of several Chinese stocks are trading lower after China’s central bank made cuts to its one-year loan prime rate and five-year rate amid attempts to stimulate the country’s economic recovery.

According to Reuters, China has implemented its first reduction in key lending benchmarks in 10 months. The move aims to support a decelerating economic recovery. However, due to concerns regarding the property market, the easing measures were not as extensive as anticipated.

See Also: What’s Going On With Ford Shares

The one-year loan prime rate (LPR) was decreased by 10 basis points to 3.55%, while the five-year LPR saw a similar reduction to 4.20%, per Reuters. This monetary loosening occurs as China experiences a slowdown in the initial momentum observed during the first quarter.

According to data from Benzinga Pro, NetEase has a 52-week high of $101.92 and a 52-week low of $53.09.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

FDA Experts Weigh In On Incannex’s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

By Jelena Martinovic
May 7, 12:35 PM
Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.

IXHL

Read More

NightHawk Biosciences Announces Planned Name Change To Scorpius Holdings, Reflecting Successful Transition To A Large Molecule Biomanufacturing CDMO; In Connection With The Name Change, The Company’s Ticker Will Change To “SCPX”

By Benzinga Newsdesk
January 8, 9:55 AM
NightHawk Biosciences (NYSE:NHWK, NHWK)), an integrated contract development and manufacturing organization (CDMO), today announced that it is changing the name of the Company to Scorpius Holdings, Inc. ("Scorpius") to

NHWK